UNLABELLED: The prevalence of high-risk human papillomavirus (hrHPV) types varies across countries, making it essential to estimate prevalence using nationwide samples. Data on hrHPV prevalence in the Czech Republic are very limited. This study aimed to determine the prevalence of various hrHPV types in an unselected screening population of Czech women aged 30-65 years, using paired clinician-obtained cervical swab (CS) and self-collected cervicovaginal swabs (CVS). A total of 1026 eligible women were recruited into two study arms. In arm A, the digene® HC2 DNA Collection Device was used for both CS and CVS. In arm B, the Evalyn Brush was used for CVS, while the Cervex Brush was used for CS. All samples were tested for hrHPV using the digene® HC2 High-Risk HPV DNA Test and genotyped with the PapilloCheck® HPV-Screening assay. The overall hrHPV prevalence was 14.8%, based on positive results from either CVS or CS samples. hrHPV positivity was detected in 10.8% of clinician-obtained CSs and 11.8% of self-collected CVSs. A combined analysis of CS and CVS samples identified the five most prevalent hrHPV genotypes: HPV16, HPV31, HPV39, HPV56, and HPV68. The comparison of hrHPV detection in paired CS and CVS samples showed an overall concordance of 93%. These findings highlight the importance of detecting hrHPV genotypes alongside conventional Pap testing in national cervical screening programs. Furthermore, the results confirm that self-sampling kits represent a suitable alternative to clinician-collected samples. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov Identifier (NCT04133610).

Cancer Research Czech Republic Olomouc The Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc The Czech Republic

Institute of Molecular and Translational Medicine University Hospital Olomouc The Czech Republic

Zobrazit více v PubMed

International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2024. https://gco.iarc.who.int (25 June 2024, date last accessed).

Wojtyla C, Ciebiera M, Kowalczyk D  et al.  Cervical cancer mortality in East-Central European countries. Int J Environ Res Public Health  2020;17:4639. 10.3390/ijerph17134639. PubMed DOI PMC

Bruni L, Serrano B, Roura E  et al.  Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Heal  2022;10:e1115–27. 10.1016/S2214-109X(22)00241-8 PubMed DOI PMC

Ngo O, Chloupková R, Cibula D  et al.  Direct mailing of HPV self-sampling kits to women aged 50-65 non-participating in cervical screening in the Czech Republic. Eur J Public Health  2024;34:361–7. 10.1093/eurpub/ckad229 PubMed DOI PMC

IARC. Cervical cancer screening. IARC Handbook Cancer Prevention, Vol. 18. 2022, 1–456. https://publications.iarc.fr/604 (25 June 2024, date last accessed).

Arbyn M, Ronco G, Anttila A  et al.  Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine  2012;30:F88–99. 10.1016/j.vaccine.2012.06.095 PubMed DOI

Arbyn M, Smith SB, Temin S, et al.  Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ  2018;363:k4823. 10.1136/bmj.k4823 PubMed DOI PMC

Bruni L, Albero G, Serrano B  et al. ICO/IARC information Centre on HPV and cancer (HPV information Centre). human papillomavirus and related diseases in the world. Summary Report. 10 March 2023. https://hpvcentre.net/statistics/reports/XWX.pdf (25 June 2024, date last accessed).

Májek O, Dušková J, Dvořák V  et al.  Performance indicators in a newly established organized cervical screening programme: registry-based analysis in the Czech Republic. Eur J Cancer Prev  2017;26:232–9. 10.1097/CEJ.0000000000000236. PubMed DOI

Jaworek H, Koudelakova V, Drabek J  et al.  A head-to-head analytical comparison of cobas 4800 HPV, PapilloCheck HPV screening, and LMNX genotyping kit HPV GP for detection of human papillomavirus DNA in cervical and cervicovaginal swabs. J Mol Diagn  2018;20:849–58. 10.1016/j.jmoldx.2018.07.004 PubMed DOI

Fairfax MR, Salimnia H.  Diagnostic molecular microbiology: a 2013 snapshot. Clin Lab Med  2013;33:787–803. 10.1016/j.cll.2013.08.003 PubMed DOI PMC

Koliopoulos G, Nyaga VN, Santesso N  et al.  Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev  2017;8:CD008587. 10.1002/14651858.CD008587.pub2 PubMed DOI PMC

Snijders PJF, Verhoef VMJ, Arbyn M  et al.  High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer  2013;132:2223–36. 10.1002/ijc.27790 PubMed DOI

Poljak M, Seme K, Maver PJ, et al.  Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine  2013;31:H59–70. 10.1016/j.vaccine.2013.03.029 PubMed DOI

Bruni L, Diaz M, Castellsagué X  et al.  Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis  2010;202:1789–99. 10.1086/657321 PubMed DOI

Tachezy R, Smahelova J, Kaspirkova J  et al.  Human papillomavirus type-specific prevalence in the cervical cancer screening population of czech women. PLoS One  2013;8:e79156. 10.1371/journal.pone.0079156 PubMed DOI PMC

de Sanjosé S, Diaz M, Castellsagué X  et al.  Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis  2007;7:453–9. 10.1016/S1473-3099(07)70158-5 PubMed DOI

Sargent A, Bailey A, Almonte M  et al.  Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer  2008;98:1704–9. 10.1038/sj.bjc.6604324 PubMed DOI PMC

Alrajjal A, Pansare V, Choudhury MSR  et al.  Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of uterine cervix and Bethesda system. Cytojournal  2021;18:16. 10.25259/Cytojournal_24_2021 PubMed DOI PMC

Pimenoff VN, Tous S, Benavente Y  et al.  Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: results from a worldwide cross-sectional study. Int J Cancer  2019;144:2478–88. 10.1002/ijc.31964 PubMed DOI

De Vuyst H, Clifford G, Li N  et al.  HPV infection in Europe. Eur J Cancer  2009;45:2632–9. 10.1016/j.ejca.2009.07.019 PubMed DOI

Arbyn M, Verdoodt F, Snijders PJF  et al.  Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol  2014;15:172–83. 10.1016/S1470-2045(13)70570-9 PubMed DOI

Belinson JL, Hu S, Niyazi M  et al.  Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: implications for vaginal self-collection. Int J Cancer  2010;127:1151–7. 10.1002/ijc.25144 PubMed DOI

Simonsen M, Tavares Guerreiro Fregnani JH, Possati Resende JC  et al.  Comparison of the Cervex-Brush PubMed DOI PMC

Depuydt CE, Benoy IH, Bailleul EJ  et al.  Improved endocervical sampling and HPV viral load detection by Cervex-Brush combi. Cytopathology  2006;17:374–81. 10.1111/j.1365-2303.2006.00386.x PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT04133610